Full Breakdown
Regeneron’s fianlimab Melanoma Trial Fails to Meet Primary Endpoint
5/19/2026, 11:55:10 AM
Regeneron’s Late-Stage Melanoma Trial Misses Primary Endpoint
Regeneron Pharmaceuticals reported that its Phase 3 study of anti-LAG-3 antibody fianlimab combined with PD-1 inhibitor cemiplimab (Libtayo) did not achieve statistical significance for improving progression-free survival (PFS) in patients with unresectable or metastatic advanced melanoma. The result was disclosed late on Friday, May 18, 2026.
Background: Oncology Strategy and Recent Setbacks
Regeneron relies on oncology to complement its eye drug Eylea and anti-inflammatory Dupixent. The melanoma study follows prior setbacks, notably U.S. delays for a pre-filled Eylea syringe and the 2025 Phase 3 failure of lung-disease candidate itepekimab. Regeneron also announced a partnership with Parabilis Medicines that could yield up to $2.2 billion in milestones.
Trial Design and Results
The double-blind trial enrolled 1,546 patients in four arms: high-dose fianlimab + cemiplimab, low-dose fianlimab + cemiplimab, Merck’s Keytruda alone, and Libtayo + placebo. The high-dose regimen showed a median PFS of 11.5 months versus 6.4 months for Keytruda—a roughly five-month numerical advantage—but the p-value of 0.0627 exceeded the 0.05 significance threshold, so the result was not statistically significant. Some reports framed the benefit as “about five months longer” without exact figures.
Market Reaction and Analyst Responses
Regeneron’s shares dropped 11-13 % in pre-market trading, wiping out about $9 billion in market value. Ten brokerages cut price targets, and BMO Capital Markets analyst Evan Seigerman warned of heightened pressure on the next 12-to-18 months of development. Regeneron said the complete data will be presented at an upcoming medical conference and noted its ongoing head-to-head Phase 3 trial of fianlimab versus Bristol Myers Squibb’s Opdualag.
Criticism and Concerns
Analysts voiced skepticism about Regeneron’s pipeline. Evercore’s Cory Kasimov called the outcome “the worst-case scenario,” and RBC’s Brian Abrahams called it a “disappointment,” warning that skeptics may more vocally question the company’s overall direction. Observers also note the reliance on a single oncology candidate for future revenue.
Conflicting Reports & Gaps
Sources vary on key numbers. Some report a median PFS of 11.5 months for the high-dose arm, while others describe the benefit only as “about five months longer” than Keytruda; the p-value of 0.0627 appears in only one report. Stock declines are cited as 11 %, 12 % or 13 %, and brokerages cutting targets range from “at least ten” to “at least two.” Efficacy data for the low-dose arm were not released.
Verbatim Quotes
- “Back-to-back key pipeline misses amp up the pressure on the next 12 to 18 months of clinical development,” — Evan Seigerman, BMO Capital Markets analyst
- “These results are the worst-case scenario,” — Cory Kasimov, Evercore analyst
- “most had expected [fianlimab] to work,” — Brian Abrahams, RBC Capital Markets
- “Cutting-edge and diversified science,” — George Yancopoulos, Regeneron co-chair & chief scientific officer
What’s Next
Regeneron will continue its head-to-head Phase 3 comparison of fianlimab + cemiplimab versus Opdualag, with results expected in 2027. The company also plans to disclose the complete melanoma trial data at a forthcoming oncology conference and to advance its partnership with Parabilis Medicines toward additional hard-to-target disease programs.
